產品詳情
簡單介紹：
Anti-NLRP7抗體產品質量穩定，實驗效果明顯，貨期快，價格優惠，歡迎垂詢訂購！我公司長期供應**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-NLRP7抗體用于**組化實驗,WB實驗,相應的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-NLRP7
Cat. Number:
Anti-NLRP7抗體KL-6866R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
This gene encodes a member of the NACHT, leucine rich repeat, and PYD containing (NLRP) protein family. It has an N-terminal pyrin domain, followed by a NACHT domain, a NACHT-associated domain (NAD), and a Anti-NLRP7抗體C-terminal leucine-rich repeat (LRR) region. NLRP proteins are implicated in the activation of proinflammatory caspases through multiprotein complexes called inflammasomes. This gene may act as a feedback regulator of caspase-1-dependent interleukin 1-beta secretion. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008].
Also known as:
CLR19.4; FLJ94610; HYDM; NACHT, leucine rich repeat and PYD containing 7; NACHT, LRR and PYD containing protein 7; NACHT, LRR and PYD domains containing protein 7; NACHT, LRR and PYD domains-containingAnti-NLRP7抗體 protein 7; NALP7; NALP7_HUMAN; NLR family, pyrin domain containing 7; NLRP7; NOD12; Nucleotide-binding oligomerization domain protein 12; Nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 7; PAN7; PYPAF3; PYRIN-containing APAF1-like protein 3.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, .
●
Immunogen: KLH conjugated Anti-NLRP7抗體synthetic peptide derived from human NLRP7.
●
Predicted Molecular Weight: 108kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-NLRP7抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-NLRP7抗體
Optimal working dilutions must be determined by the end user.
